| Name | Methotrexate |
| Description | Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors. |
| Cell Research | Methotrexate (MTX) is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Each cell line is studied in growth inhibition experiments using 96-well microtiter plates. As antifols are schedule dependent, preliminary experiments are aimed at defining the longest duration of exposure that would allow for continuous logarithmic phase growth of cells without changing of the culture media while maintaining a linear relationship between SRB optical density and cell number. Twenty-four hours after cell plating, the cell lines are exposed to the antifol for 120 h (three replicates per experiment). To ensure that a complete sigmoidal survival-concentration curve could be observed, the following drug concentrations are studied: Methotrexate (0.002-5 μM), AMT (0.0001-1 μM), PXD (0.0003-10 μM), TLX (0.0002-0.5 μM). Experiments are repeated at least twice[1]. |
| In vitro | METHODS: Six pediatric leukemia and lymphoma cell lines, NALM-6, NALM-16, JURKAT, CEM, RAMOS, and NAMALWA, were treated with Methotrexate (0.002-5 μM) for 120 h, and the proliferation inhibitory activity of the cells was assayed using the SRB method.
RESULTS: The median IC50 of Methotrexate against tumor cells was 78 nM, and the IC50 of the six tumor cells ranged from 33-133 nM. [1]
METHODS: Human ovarian cancer cells SKOV-3 were treated with Methotrexate (15-50 μM) for 24 h. Apoptosis was detected using AO/EtBr probe.
RESULTS: Methotrexate induced apoptosis in SKOV-3 cells. [2] |
| In vivo | METHODS: To test for chronic toxicity, Methotrexate (0.25-6 mg/kg) was administered intraperitoneally to C57BL/6, DBA/2, and C3H mice five times per week for 12-18 months.
RESULTS: The 0.25-2 mg/kg dose was well tolerated with minimal cytostasis in lymphoid tissues, testis and skin. 3-6 mg/kg dose produced well-known acute to subacute hematopoietic and gastrointestinal injuries leading to early death. [3]
METHODS: To examine the mode of action in different types of rheumatoid arthritis (RA) and multiple sclerosis (MS) models, Methotrexate (0.1-5 mg/kg) was injected intraperitoneally once a day for fourteen days into RA and MS models with different pathogenesis.
RESULTS: Methotrexate showed strong ameliorative effects in classical RA models such as CIA and PIA as well as in MS and EAE models.Methotrexate acts only prior to and dependent on T-cell activation in T-cell activated diseases. [4] |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (99.02 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.3 mg/mL (18.26 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
|
| Keywords | NCI-C 04671 | WR-19039 | antineoplastic | WR 19039 | DNA/RNA Synthesis | Apoptosis | ADC Cytotoxin | arthritis | rheumatoid | Antifolate | synthesis | ADC Payload | Inhibitor | lymphoblastic | reductase | leukemia | immunosuppressant | Methotrexate | NCI-C-04671 | CL-14377 | inhibit | DNA | CL 14377 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Guanidine hydrochloride | Metronidazole | Tributyrin | Thymidine |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
